BioCardia Stock
BioCardia, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Peter A. Altman
- Employees
- 17
- Market cap
- $14 M
- IPO
- 13/11/1996
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and…
BioCardia stock: price history
1D
-2.0%
1W
-11.5%
1M
-26.4%
6M
-22.0%
YTD
-26.4%
1Y
-36.5%
2Y
-65.1%
5Y
-99.3%
10Y
-99.8%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~56% weaker price swings than usual
Ask the agents about BioCardia
Analyst assessment of BioCardia
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 24/08/2026
BioCardia stock metrics
P/E
-1.21
P/B
4.12
EV/EBITDA
-1.4
RETURN ON EQUITY
-59.7%
NET MARGIN
0.0%
DEBT/EQUITY
0.11
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.0%
FLOAT SHARES
12,260,900
AVG. DAILY VOLUME (30D)
286,407
Insider transactions (SEC)
Altman Peter
Altman Peter
Altman Peter
Altman Peter
Altman Peter
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about BioCardia stock
What does BioCardia do?
BioCardia, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Peter A. Altman, the company employs around 17 people.
The IPO was on 13/11/1996; the stock trades on NASDAQ under the ticker BCDA.
What do analysts say about BioCardia stock?
5 analysts rate the stock, the consensus is Buy (as of 24/08/2026).
This is an external assessment, not a statement by Market Jury.
When does BioCardia report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -56% stronger than usual.
Does BioCardia pay a dividend?
No, BioCardia currently does not pay a dividend.
Which stocks are comparable to BioCardia?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get BioCardia stock analyzed?
Clicking "Analyze stock" lets five strategies assess BioCardia against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.